In this episode, Sacha Hebbert chats with the world's leading nutritional biochemist and thought leader on human optimization, Shawn Wells. Shawn has created 1,000 supplement wellness products and sits on 25 novel ingredient patents. We get his perspective on psychedelics and how they saved his life.
With the incredible popularity of “How to Change Your Mind,” Michael Pollan sells people on psychedelic treatments that are not yet available
The bronze age psychedelics: hair strands unveil Europe’s earliest recorded hallucinogenic drug use 3000 years ago.
In a tight race that came down the wire, Colorado voters approve Measure 122 to decriminalize small amounts of psychedelic drugs
Who’s next in line to Uplist to the Nasdaq? Numinus? Cybin? FieldTrip? ALL of them??
Today, I’ll be covering an article by Jeff Neilson published on The Psychedelic Stock Watch. In this article, Jeff outlines several stocks as contenders for an uplisting.
* Cybin Inc (CAN:CYBN / US:CLXPF) : Cybin is also one of the more successful companies in raising capital, having raised ~CAD$88.8 million (US$70 million) since going public last November and as we have been repeating on this channel, capital is a very important factor for the successful continuation and advancement of clinical trials.
*Field Trip Health (CAN:FTRP / US:FTRPF) : Field Trip Health shares some similarities with Cybin as an uplisting prospect. It has raised even more capital than Cybin, in excess of US$100 million, including its recent CAD$95 million bought deal financing (US$76 million) and Field Trip has also a price target of CAD$8.50 price target from Stifel GMP to its February 2021 high of CAD$8.25.
*Numinus Wellness (CAN:NUMI / US:LKYSF) : Numinus Wellness actually has a stronger following among retail investors than either Cybin or Field Trip. It was second only to MindMed as the volume leader among psychedelic stocks in the 2020 rally. It was also the second-best performer among all of the leading stocks in that rally, generating a 10X return at its 2020 peak.
However, these are not the only psychedelic stocks to peak Jeff Neilson’s eye.
He also mentions:
Mind Cure Health (CAN:MCUR / US:MCURF)
Mydecine Innovations Group (CAN:MYCO / US:MYCOF)
Bright Minds Biosciences (CAN:DRUG / US:BMBIF)
Small Pharma Inc( it hasn’t even started public trading YET)
Timestamps:
0:00 – Intro
1:55 – Cybin ( CYBN / CXPF )
6:13 – Field Trip Health ( FTRP / FTRPF )
9:05 – Numinus Wellness ( NUMI / LKYSF )
11:35 – Mindcure Health
12:08 – Mydecine ( MYCO /MYCOF )
12:34 – Bright Minds Biosciences ( DRUG / BMBIF )
13:10 – Small Pharma Inc.
Link to the article in question: https://psychedelicstockwatch.com/psychedelic-stock-news/the-next-psychedelic-stock-to-uplist-on-the-nasdaq?fbclid=IwAR3CgezfqtNHk0U3_YX5LYHDU2Y34jEFSTdNVGVchsKgR4CdEj58Q-lYcwk
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Canacord: https://thetradingpriest.com/wp-content/uploads/2021/04/ResearchReport-1.pdf
Link to Numinus (NUMI): https://numinus.ca/
Link to Field Trip ( FTRP / FTRPF) : https://www.fieldtriphealth.com/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Cybin #Numi
THE MINDMED VS. ATAI discussion you need to hear!
Prior to atai’s IPO on the NASDAQ stock exchange, we repeatedly said that when atai Life Sciences goes public, the company will become MindMed ‘s ( MNMD: NASDAQ) (MMED: NEO) top competitor.
Well, atai did IPO on June 18 under ticker symbol “atai”. For this reason, I invited Jason Najum from Microdose.buzz to have a conversation. In this episode, we have a general discussion about:
– MindMed’s flagship programs and the different businesses and programs ran under atai’s umbrella.
– The companies’ financial capability to run clinical trials.
-MindMed’s and atai’s potential to disrupt the way we treat mental illness within the next 5 to 10 years.
– Potential return on investment for retail investors.
Time Stamps:
0:00 – Intro
4:11 – What is atai’s mission?
6:24 – What is MindMed’s Mission
8:29 – atai’s clinical trial pipeline
19:45 – MindMed’s clinical trial pipeline
24:25 – How do MindMed and atai differ in business structure?
30:40 – Comparing the financials
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Enjoy the episode!
Check out Jason’s writing at:
https://microdose.buzz/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #Atai
Dr. Matthew Johnson, one of the most published psychedelics researchers in the world, shares two decades worth of wisdom.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
